Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBITDA Margin (2016 - 2025)

Vanda Pharmaceuticals' EBITDA Margin history spans 16 years, with the latest figure at 70.0% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 5117.0% year-over-year to 70.0%; the TTM value through Dec 2025 reached 69.44%, down 4944.0%, while the annual FY2025 figure was 69.44%, 4944.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 70.0% at Vanda Pharmaceuticals, down from 55.07% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 18.72% in Q2 2021 and bottomed at 81.53% in Q1 2025.
  • The 5-year median for EBITDA Margin is 13.57% (2022), against an average of 15.8%.
  • The largest annual shift saw EBITDA Margin soared 1666bps in 2021 before it tumbled -6250bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 13.25% in 2021, then decreased by -19bps to 10.69% in 2022, then crashed by -242bps to 15.22% in 2023, then dropped by -24bps to 18.83% in 2024, then tumbled by -272bps to 70.0% in 2025.
  • Per Business Quant, the three most recent readings for VNDA's EBITDA Margin are 70.0% (Q4 2025), 55.07% (Q3 2025), and 72.71% (Q2 2025).